Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 18/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18844825 | 0.86 | FBP1 (0.59) | P2RY2FBP1P2RY6 | |
| SCHEMBL15293066 | 0.86 | FBP1 (0.59) | P2RY2FBP1P2RY6 | |
| SCHEMBL17789075 | 0.86 | FBP1 (0.59) | P2RY2FBP1P2RY6 | |
| SCHEMBL14928402 | 0.86 | FBP1 (0.59) | P2RY2FBP1P2RY6 | |
| SCHEMBL24245871 | 0.85 | P2RY2 (0.47) | P2RY2P2RY4FBP1P2RY6 | |
| SCHEMBL14406690 | 0.85 | FBP1 (0.53) | P2RY2P2RY4FBP1 | |
| SCHEMBL12374598 | 0.85 | FBP1 (0.53) | P2RY2P2RY4FBP1 | |
| SCHEMBL17732505 | 0.84 | P2RY2 (0.45) | P2RY2P2RY4FBP1P2RY6 | |
| SCHEMBL18603979 | 0.82 | P2RY2 (0.36) | P2RY2P2RY4P2RY6 | |
| SCHEMBL271882 | 0.82 | P2RY2 (0.36) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | disclosed |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | TYMP, MTAP, GART | P2RY2 1101/4885P2RY4 732/4885FBP1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.